PolyPid to Deliver Poster Presentation at SAGES 2022

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) will present clinical data for its lead product D-PLEX₁₀₀ at the SAGES 2022 Annual Meeting in Denver from March 16-19, 2022. The poster presentation evaluates D-PLEX₁₀₀'s effectiveness in reducing surgical site infections in elective colorectal surgery when combined with standard prophylaxis. Dr. Anthony Senagore, Senior Medical Director, will lead the oral review. D-PLEX₁₀₀ is currently in Phase 3 trials aimed at preventing infections after abdominal and sternal surgeries.

Positive

• D-PLEX₁₀₀ is in Phase 3 clinical trials focused on preventing surgical site infections.
• The upcoming presentation at SAGES 2022 highlights clinical data supporting D-PLEX₁₀₀.
• Potential to improve surgical outcomes could enhance market position.

Negative

• None.

Presentation Evaluates Efficacy of D-PLEX₁₀₀ in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery

PETACH TIKVA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes announced it will be presenting clinical data at the upcoming SAGES (Society of American Gastrointestinal and Endoscopic Surgeons) 2022 Annual Meeting, being held on March 16-19, 2022 in Denver, Colorado.

The poster presentation entitled ‘DPLEX_100, a Novel Doxycycline Formulation that Provides High, Local Concentrations of Antibiotic Activity for Approximately Four Weeks to Reduce Surgical Site Infections’ evaluates the efficacy of PolyPid’s lead drug candidate D-PLEX₁₀₀ in reducing surgical site infections when added to standard of care prophylaxis regimens for elective colorectal surgery. The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be available on https://www.polypid.com/ following the delivery of the presentation.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Corporate Contact:

PolyPid, Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investor Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
FINN Partners
551-444-0784
Nechama.Feuerstein@finnpartners.com

FAQ

What is PYPD's lead product candidate?

PolyPid's lead product candidate is D-PLEX₁₀₀, aimed at reducing surgical site infections.

When is PolyPid presenting at SAGES 2022?

PolyPid will present clinical data at the SAGES 2022 Annual Meeting from March 16-19, 2022.

What is the focus of the presentation about D-PLEX₁₀₀?

The presentation evaluates the efficacy of D-PLEX₁₀₀ in reducing surgical site infections during elective colorectal surgeries.

Who will lead the oral review of D-PLEX₁₀₀ at the presentation?

Dr. Anthony Senagore, Senior Medical Director of PolyPid, will lead the oral review.